JDW312 enhances gemcitabine efficacy in pancreatic cancer through ROS/MEK/ERK activation
Bioorganic Chemistry · 2026-11 · 184 · 110656
DOI: 10.1016/j.bioorg.2026.110656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Wang Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Luoyang Key Laboratory of Organic Functional Molecules, School of Food and Drug, Luoyang Normal University, Luoyang, 471934, China; Henan Provincial …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Deoxycytidine, Antineoplastic Agents. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Pancreatic cancer is a highly aggressive malignancy with late diagnosis, early metastasis, poor prognosis, and limited therapeutic options. To address this unmet clinical need, we employed JOA as a lead compound and developed its derivative, JDW312, through structural optimization. The effects and underlying mechanisms of JDW312 were investigated using cell proliferation assays, flow cytometry, Western blotting, immunohistochemistry, and SW1990 xenograft models. In vitro, JDW312 exhibited potent and moderately selective anti-proliferative activity against pancreatic cancer cells SW1990 (IC50 = 0.93 ± 0.08 μM), primarily through activation of the ROS/MEK/ERK signaling pathway, leading to apoptosis and autophagy induction and suppression of cell proliferation. In vivo, JDW312 (20 mg/kg, tumor inhibition rate 53.04%) showed significantly greater anti-tumor efficacy than oridonin (20 mg/kg, tumor inhibition rate 25.16%). Moreover, its combination with gemcitabine markedly enhanced anti-tumor activity while maintaining a tolerable safety profile. Collectively, these findings identify JDW312 as a promising therapeutic candidate for pancreatic cancer, either alone or in combination with standard chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Luoyang Key Laboratory of Organic Functional Molecules, School of Food and Drug, Luoyang Normal University, Luoyang, 471934, China; Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzho…
- School of Pharmaceutical Sciences; Institute of Drug Discovery and Development; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
- Luoyang Key Laboratory of Organic Functional Molecules, School of Food and Drug, Luoyang Normal University, Luoyang, 471934, China.
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Electronic address: 20111030063@fudan.edu.cn.
- School of Pharmaceutical Sciences; Institute of Drug Discovery and Development; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China. Elect…
Zitieren
APA
Wang, W., Ding, X., Liu, H., Miao, Y., Geng, M., Huang, Q., Cui, Y., Gao, F., Guo, Y., Jing, S., Xie, H., Liu, H., & Ke, Y. (2026). JDW312 enhances gemcitabine efficacy in pancreatic cancer through ROS/MEK/ERK activation. Bioorganic Chemistry, 184, 110656. https://doi.org/10.1016/j.bioorg.2026.110656
Vancouver
Wang W, Ding X, Liu H, Miao Y, Geng M, Huang Q, et al. JDW312 enhances gemcitabine efficacy in pancreatic cancer through ROS/MEK/ERK activation. Bioorganic Chemistry. 2026;184:110656. doi:10.1016/j.bioorg.2026.110656
BibTeX
@article{Wang2026,
author = {Wang, Wang and Ding, Xinfang and Liu, Haibin and Miao, Yanan and Geng, Mingge and Huang, Qile and Cui, Yafei and Gao, Feixiang and Guo, Yue and Jing, Shuo and Xie, Hang and Liu, Hongmin and Ke, Yu},
title = {JDW312 enhances gemcitabine efficacy in pancreatic cancer through ROS/MEK/ERK activation},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {184},
pages = {110656},
doi = {10.1016/j.bioorg.2026.110656}
}
EUVIMED